c-MET antibody (AA 83-209)

Catalog No. ABIN7155043

Product Details anti-c-MET Antibody

Target: c-MET (MET) (Met Proto-Oncogene (MET))

Binding Specificity: AA 83-209

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This c-MET antibody is un-conjugated

Application: ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human Hepatocyte growth factor receptor protein (83-209AA)

Isotype: IgG

Application Details

Application Notes: Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for c-MET

Target: c-MET (MET) (Met Proto-Oncogene (MET))

Alternative Name: MET (MET Products)

Synonyms: AUTS9 antibody, HGFR antibody, RCCP2 antibody, c-Met antibody, AI838057 antibody, HGF antibody, Par4 antibody, Hgfr antibody, c-met antibody, MET antibody, C-MET antibody, met antibody, met-A antibody, MET proto-oncogene, receptor tyrosine kinase antibody, met proto-oncogene antibody, MET proto-oncogene, receptor tyrosine kinase L homeolog antibody, MET antibody, Met antibody, met.L antibody

Background:

Background: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity).

Aliases: AUTS9 antibody, c met antibody, D249 antibody, Hepatocyte growth factor receptor antibody, HGF antibody, HGF receptor antibody, HGF/SF receptor antibody, HGFR antibody, MET antibody, Met proto oncogene antibody, Met proto oncogene tyrosine kinase antibody, MET proto oncogene, receptor tyrosine kinase antibody, Met proto-oncogene (hepatocyte growth factor receptor) antibody, Met proto-oncogene antibody, Met protooncogene antibody, MET_HUMAN antibody, Oncogene MET antibody, Par4 antibody, Proto-oncogene c-Met antibody, RCCP2 antibody, Scatter factor receptor antibody, SF receptor antibody, Tyrosine-protein kinase Met antibody

UniProt: P08581

Pathways: RTK Signaling, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor